

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

宜昌東陽光長江藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 01558)

**COMPLETION OF REPURCHASE OF THE US\$400,000,000 3.0%
H SHARE CONVERTIBLE BONDS IN FULL**

References are made to the announcements of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the “**Company**”) dated 14 August 2018, 20 February 2019, 16 June 2020, 8 September 2022, 13 January 2023, 27 February 2023, 9 March 2023 and 30 June 2023 (the “**Announcements**”) and the circular of the Company dated 11 September 2018 (the “**Circular**”), in relation to, among others, the US\$400,000,000 3.0% H Share convertible bonds issued by the Company (the “**Bonds**”) and the partial repurchases of the Bonds. Terms defined in the Announcements and the Circular have the same meaning when used in this announcement unless the context otherwise requires.

As disclosed in the announcement of the Company dated 30 June 2023, the Company entered into a supplemental agreement to the third bond purchase agreement in respect of the Second Trench Repurchased Bonds (the “**Supplemental Agreement**”), pursuant to which the parties agreed to revise the purchase price for the repurchase of the Second Trench Repurchased Bonds from US\$278,191,332 to US\$263,191,332, and the repurchase shall be completed on or before 5 July 2023.

The Board hereby announces that on 5 July 2023, the repurchase contemplated under the Supplemental Agreement has been completed. Upon completion of the repurchase, the principal amount of the Bonds has been repurchased in full and the Seller will no longer have any interest in the Bonds and/or any rights arising therefrom.

On behalf of the Board

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

TANG Xinfa

Chairman

Hubei, the People's Republic of China
5 July 2023

As at the date of this announcement, the Board consists of Mr. JIANG Juncai, Mr. WANG Danjin, Mr. CHEN Yangui and Mr. LI Shuang as executive Directors; Mr. TANG Xinfa as non-executive Director; and Mr. TANG Jianxin, Ms. XIANG Ling and Mr. LI Xuechen as independent non-executive Directors.